May 18, 2020 / 4:14 AM / 10 days ago

BRIEF-Luye Pharma Says MAA For Rivastigmine MD Accepted For Review By EU Authorities

May 18 (Reuters) - Luye Pharma Group Ltd:

* MARKETING AUTHORIZATION APPLICATION FOR RIVASTIGMINE MD TO TREAT ALZHEIMER’S ACCEPTED FOR REVIEW BY EU COMPETENT AUTHORITIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below